GENERAL29 Sept 2026
Zydus hits 52-week high, can the optimism continue? | Stock Market News
Zydus Lifesciences shares hit a fresh 52-week high of ₹1,232.10 after two US Food and Drug Administration (FDA) inspections closed with almost no observations. The stock is up 32% in 2026. India business grew 19.5%, but US sales fell 12% and margins dropped 750 bps. If you hold pharma stocks, watch US sales and margin trends before adding more.
Key Statutory Highlights
- Zydus Lifesciences shares reached a 52-week high of ₹1,232.10 and have gained 32% in 2026, ahead of an 18% rise in the Nifty Pharma Index.
- Two US FDA inspections closed with nil observations at its New Jersey office and only one observation at its Ahmedabad SEZ II plant.
- US sales, which were 40% of revenue in the June quarter, fell 12% in constant currency, while Ebitda margin dropped 750 bps to 23.4%.
- Domestic formulations grew 19.5% year-on-year to ₹1,820 crore and contributed 23% of Q1 revenues.
Actionable Advice for Taxpayers / Founders:If you hold or plan to buy Zydus shares, review its quarterly US sales and margin numbers before taking any decision, and check with your financial adviser.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: